Advertisement
Research Article

National Mass Drug Administration Costs for Lymphatic Filariasis Elimination

  • Ann S. Goldman mail,

    sphasg@gwumc.edu

    Affiliation: Department of Epidemiology and Biostatistics, The George Washington School of Public Health and Health Services, Washington, DC, United States of America

    X
  • Victoria H. Guisinger,

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Moses Aikins,

    Affiliation: Health Research Unit, Ghana Health Service, Accra, Ghana

    X
  • Maria Lourdes E. Amarillo,

    Affiliation: Department of Clinical Epidemiology, College of Medicine, University of the Philippines, Manila, The Philippines

    X
  • Vicente Y. Belizario,

    Affiliation: Department of Parasitology, College of Public Health, University of the Philippines, Manila, The Philippines

    X
  • Bertha Garshong,

    Affiliation: Health Research Unit, Ghana Health Service, Accra, Ghana

    X
  • John Gyapong,

    Affiliation: Health Research Unit, Ghana Health Service, Accra, Ghana

    X
  • Conrad Kabali,

    Affiliation: National Institute of Medical Research, Dar es Salaam, Tanzania

    X
  • Hussein A. Kamal,

    Affiliation: Ministry of Health & Population, Cairo, Egypt

    X
  • Sanjat Kanjilal,

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Dominique Kyelem,

    Affiliation: Lymphatic Filariasis Program, Ministry of Health, Ouagadougou, Burkina Faso

    X
  • Jefrey Lizardo,

    Affiliation: Center for Social Management, Technological Institute of Santo Domingo, Santo Domingo, Dominican Republic

    X
  • Mwele Malecela,

    Affiliation: National Institute of Medical Research, Dar es Salaam, Tanzania

    X
  • Godfrey Mubyazi,

    Affiliation: National Institute of Medical Research, Dar es Salaam, Tanzania

    X
  • P. Abdoulaye Nitièma,

    Affiliation: Department of Evaluation, Ministry of Health, Ouagadougou, Burkina Faso

    X
  • Reda M. R. Ramzy,

    Affiliation: Research & Training Center on Vectors of Diseases, Ain Shams University, Cairo, Egypt

    X
  • Thomas G. Streit,

    Affiliation: Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America

    X
  • Aaron Wallace,

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Molly A. Brady,

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Richard Rheingans,

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Eric A. Ottesen,

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Anne C. Haddix

    Affiliation: Lymphatic Filariasis Support Center, Emory University, Atlanta, Georgia, United States of America

    X
  • Published: October 31, 2007
  • DOI: 10.1371/journal.pntd.0000067

Reader Comments (1)

Post a new comment on this article

Why this paper helps...

Posted by CHKing on 08 Dec 2007 at 21:46 GMT

Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk.Methodol
http://plosntds.org/article/info:doi/10.1371/journal.pntd.0000067#article1.front1.article-meta1.abstract1.sec1.p1

The advance provided by this paper is the parallel analysis of costs data on the efforts for Lymphatic Filariasis elimination. Accurate cost-effectiveness analysis requires inputs such as these, across a range of locations and a range of program structures. Those who are concerned about the continued participation of Community Health volunteers will be able to examine available results from various settings.
Charles King
Academic Editor